For US residents only.

How Treatment May Help

AFINITOR Tablets

AFINITOR SHRINKS TSC-RELATED KIDNEY TUMORS AND MAY PREVENT NEW ONES FROM GROWING

In a 4-year study, AFINITOR® (everolimus) Tablets reduced the size of kidney tumors, starting at 6 months and continuing through 4 years. In the extension study, a total of 112 patients (79 patients received AFINITOR and 33 patients received placebo) participated in the study. The size of kidney tumors was measured at the start of the study, then at 12, 24, and 48 weeks—and every year from then on.

 

As early as 6 months, 42% of people had their tumor shrink to half its size

At 4 years, 58% of patients had their tumor shrink to half its size*

  • Median length of treatment was about 4 years (range: 0.5 – 63.6 months)
  • Patients also had no new kidney tumors ≥1 cm, no increase in kidney volume ≥20%, and no serious tumor-related bleeding

 

 

At 4 years, 86% of people had no progression in their kidney tumors*

*No progression meant total kidney tumor volume did not increase more than 25% from the lowest volume measured, no tumors 1 cm or longer developed, neither kidney increased in volume by 20% or more from the lowest volume measured, and no serious kidney tumor–related bleeding was seen.

 

 

At 6 months, 26% of people had a visual improvement in their skin lesions*  In these patients, there was a noticeable improvement in 50% to 99% of their skin lesions

In these patients, there was a noticeable improvement in 50% to 99% of their skin lesions.

Skin lesion response was determined for the 114 patients with ≥1 skin lesion at baseline. All skin lesion responses were partial responses, meaning there was visual improvement in 50% to 99% of all skin lesions and the improvement lasted for at least 8 weeks.